Full Press Release Details
WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA.
For more information on DDW 2019, please refer to https://ddw.org/home.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
Burson Cohn & Wolfe (BCW)
1110 Vermont Avenue, NW, Suite 1200
Washington, D.C. 20005
Burson Cohn & Wolfe (BCW)
230 Park Avenue South
SOURCE Vanda Pharmaceuticals Inc.
Related Links
21 %
more press release views with